stokkio-documentsfalsefavicon.ico169445848115895812023-09-11T18:54:41.179Z"a8a46a87bdf21de3885b97d9827ade22"15086report-3.pdf169332915121026812023-08-29T17:12:31.233Z"595042c72e65711e5ced061879c0a68d"26741testingtestingtesting/171094348145763712024-03-20T14:04:41.494Z"d41d8cd98f00b204e9800998ecf8427e"0testingtestingtesting/subtitles-test/171094349075464812024-03-20T14:04:50.793Z"d41d8cd98f00b204e9800998ecf8427e"0testingtestingtesting/subtitles-test/captions-da.vtt171094397588613512024-03-20T14:12:55.964Z"6529129172583ffbac8a39b8eaf72622"40071testingtestingtesting/subtitles-test/captions.vtt171094397528635012024-03-20T14:12:55.371Z"683a9828319b6a05278b0ec8df9edc33"40144testingtestingtesting/subtitles-test/index.html171094351182238612024-03-20T14:05:11.845Z"14d61a9d21d57b880f64bdd48a5207eb"1234transcripts/H1-2023-presentation-Brain-2023-09-01-Sentiment-Analysis.pdf169381155094338012023-09-04T07:12:30.977Z"f484c414926450f1a60f28de25d39afe"259546transcripts/H1-2023-presentation-Penneo-2023-08-17-Sentiment-Analysis.pdf169381155850296412023-09-04T07:12:38.541Z"21c5b986b40219dcd1a0a7dcc4e2557b"257985transcripts/Q2-2023-presentation-Movinn-2023-08-30-Sentiment-Analysis.pdf169381156549488312023-09-04T07:12:45.530Z"93e49167f51d1f946a8396cd3b7acda4"260239transcripts/Q2-2023-presentation-Shape-Robotics-2023-08-29-Sentiment-Analysis.pdf169381157212512812023-09-04T07:12:52.162Z"4b5566fc8425c7603974c903f6190cfc"261050transcripts/Q2-Investor-update-2cureX-2023-07-12-Sentiment-Analysis.pdf169381157817451812023-09-04T07:12:58.208Z"cd2cd1b8221fa3361cc4137c5933fcb5"248145transcripts/event-100/SaaS Seminar-DecideAct-2022-06-08-Sentiment Analysis.pdf169545542782699412023-09-23T07:50:27.892Z"5c68a79f6b8d36c5f943b9f5211df3b0"236842transcripts/event-100/SaaS Seminar-DecideAct-2022-06-08.pdf169545542607631112023-09-23T07:50:26.140Z"1814f1d69989b5cad9ab2f9e7656a07d"236362transcripts/event-101/Status update, warrant exercise and Q&A-Brain+-2023-10-02-Sentiment Analysis.pdf169635823309768712023-10-03T18:37:13.162Z"960bb08b7416581067ee34b9f9c876d1"248062transcripts/event-101/Status update, warrant exercise and Q&A-Brain+-2023-10-02.pdf169635823106709912023-10-03T18:37:11.133Z"ff0f41899ba22ee4166a6d516a64ddd2"247347transcripts/event-102/Investor Update Q3-FOM Technologies-2023-10-04-Sentiment Analysis.pdf169648361577476012023-10-05T05:26:55.792Z"52c21a608b170e0df4d04af1f45e74b2"237831transcripts/event-102/Investor Update Q3-FOM Technologies-2023-10-04.pdf169648361406029312023-10-05T05:26:54.080Z"f08b97188f71b6fe9d7db41c59ba0f6a"237402transcripts/event-103/Q3 Investor Update-2cureX-2023-10-26-Sentiment Analysis.pdf169839136363908412023-10-27T07:22:43.700Z"2a26706e13f8c49e284f7d697df05144"251357transcripts/event-103/Q3 Investor Update-2cureX-2023-10-26.pdf169839136162789312023-10-27T07:22:41.753Z"aee9fd51253cd40df370af54b76d52db"251020transcripts/event-104/Investor Update and Rights Issue Q&A-Risk Intelligence-2023-10-16-Sentiment Analysis.pdf169748112045221512023-10-16T18:32:00.519Z"9d4026ccf63c5c07f66f393f4869edb2"246184transcripts/event-104/Investor Update and Rights Issue Q&A-Risk Intelligence-2023-10-16.pdf169748111740813512023-10-16T18:31:57.477Z"ac448d9759241e0f41b1036c9c6a23e8"245681transcripts/event-105/Q3 Earnings Call-Solar-2023-11-02-Sentiment Analysis.pdf169892949836288412023-11-02T12:51:38.383Z"769131d27aadcd15d8cad4d47ca4ad4f"238618transcripts/event-105/Q3 Earnings Call-Solar-2023-11-02.pdf169892949651595812023-11-02T12:51:36.533Z"12fa281bb2acc37dc6fb0dd896f2ae16"237829transcripts/event-106/Q3 2023 presentation-Movinn-2023-11-07-Sentiment Analysis.pdf169937594831524412023-11-07T16:52:28.386Z"81558cd3947386ad1ec5e0eeaa292567"263014transcripts/event-106/Q3 2023 presentation-Movinn-2023-11-07.pdf169937594592071012023-11-07T16:52:25.984Z"4ec4b505604bcc4b611e59a1a4344f00"261805transcripts/event-107/Q3 Presentation-Shape Robotics-2023-11-22-Sentiment Analysis.pdf170065972576159212023-11-22T13:28:45.781Z"361bab7cf5d9b4dd9146432649e3e820"237908transcripts/event-107/Q3 Presentation-Shape Robotics-2023-11-22.pdf170065972215393512023-11-22T13:28:42.178Z"ec7698f79665b6322b166f79f7037063"237734transcripts/event-108/Q3 Presentation-Penneo-2023-11-21-Sentiment Analysis.pdf170058299290619212023-11-21T16:09:52.924Z"780ce809a16325d64425ce291bc89a9e"241379transcripts/event-108/Q3 Presentation-Penneo-2023-11-21.pdf170058299032340712023-11-21T16:09:50.349Z"18376bf223fcbb36a49f8ad387d919bf"240616transcripts/event-109/Q4 2022/23 Presentation-Scandinavian Medical Solutions-2023-11-23-Sentiment Analysis.pdf170074977058649712023-11-23T14:29:30.656Z"b35430acc5b4d6cbe31fd556903071b6"242267transcripts/event-109/Q4 2022/23 Presentation-Scandinavian Medical Solutions-2023-11-23.pdf170074976825211012023-11-23T14:29:28.319Z"159b7b2b2c2cd655cfb7e7624cf900a0"242057transcripts/event-110/Q3 2023 Presentation-Curasight-2023-11-27-Sentiment Analysis.pdf170118804721236012023-11-28T16:14:07.275Z"b9179780b8e3d566918236075d37d85c"241507transcripts/event-110/Q3 2023 Presentation-Curasight-2023-11-27.pdf170118804514428712023-11-28T16:14:05.210Z"f02c7bcd5bcd8cb50d8a286a4f53fd0d"241052transcripts/event-111/Q4 2022/23 Presentation-CS Medica-2023-12-05-Sentiment Analysis.pdf170177733488123912023-12-05T11:55:34.900Z"fcb5001a9a7525e92236dff4db3eedf0"242158transcripts/event-111/Q4 2022/23 Presentation-CS Medica-2023-12-05.pdf170177733293457512023-12-05T11:55:32.954Z"50f72dc53e64210ef11558fd54a6c98f"241711transcripts/event-112/Q3 2023 Presentation-Risk Intelligence-2023-12-07-Sentiment Analysis.pdf171093816409495512024-03-20T12:36:04.210Z"c0a38a4724c96ab65be25e0e241a965e"240637transcripts/event-112/Q3 2023 Presentation-Risk Intelligence-2023-12-07.pdf171093815835930412024-03-20T12:35:58.484Z"4e7f8e6af8962de98c26de4d8f03c346"240184transcripts/event-114/Rights Issue 2023-Virogates-2023-12-08-Sentiment Analysis.pdf170204653620975212023-12-08T14:42:16.227Z"abe54bb9ef874f166e125a4104bf0361"241059transcripts/event-114/Rights Issue 2023-Virogates-2023-12-08.pdf170204653409436212023-12-08T14:42:14.112Z"04dbc92d16fa3dff5fe16deb61dc6ed4"240657transcripts/event-115/Q4 Investor Update-Brain+-2024-01-18-Sentiment Analysis.pdf170559980969901212024-01-18T17:43:29.760Z"4d7bfb618b03cc816576ba21a9b85460"255351transcripts/event-115/Q4 Investor Update-Brain+-2024-01-18.pdf170559980678587412024-01-18T17:43:26.847Z"a33f8ec210f4266a3e41163d1a9c9a70"254391transcripts/event-116/Q4 Investor Update-FOM Technologies-2024-01-10-Sentiment Analysis.pdf170491746376688212024-01-10T20:11:03.784Z"78cafe477a64b3acb1f4d8e090ce0ed5"235800transcripts/event-116/Q4 Investor Update-FOM Technologies-2024-01-10.pdf170491746195250212024-01-10T20:11:01.975Z"d6047a83cbb9765608f73561b7de185d"235530transcripts/event-118/Annual Report 2023 Presentation-Konsolidator-2024-02-09-Sentiment Analysis.pdf170747971000826412024-02-09T11:55:10.027Z"0c0b761f650455887637b648411fb13a"238702transcripts/event-118/Annual Report 2023 Presentation-Konsolidator-2024-02-09.pdf170747970798115212024-02-09T11:55:08.002Z"fca72a1c13593946d8a08b50a9a82c31"238219transcripts/event-120/Annual Report 2023 presentation-Solar-2024-02-08-Sentiment Analysis.pdf170740500748217712024-02-08T15:10:07.543Z"fea818a4a26296b9ae6ef2cf5624866c"238488transcripts/event-120/Annual Report 2023 presentation-Solar-2024-02-08.pdf170740500587304812024-02-08T15:10:05.945Z"dfcff9521e05875c0369e8c19df67c90"238018transcripts/event-121/Q4 & FY2023 presentation-Curasight-2024-02-27-Sentiment Analysis.pdf170911049279427412024-02-28T08:54:52.866Z"c3dbab272fb4c61112c8f884f258e388"245740transcripts/event-121/Q4 & FY2023 presentation-Curasight-2024-02-27.pdf170911049001096012024-02-28T08:54:50.087Z"3318514094abd39332a4093c481b055c"245169transcripts/event-121/test danish issue-Shape Robotics-2024-06-11-Sentiment Analysis.pdf171819304576296912024-06-12T11:50:45.828Z"5478e087f2f9fe917246ca58a0d9bea4"254324transcripts/event-121/test danish issue-Shape Robotics-2024-06-11.pdf171819304097467512024-06-12T11:50:41.050Z"ced94915d54a9094abbc7fd934d059ad"253926transcripts/event-126/Annual Report 2022/2023 Presentation-CS Medica-2024-02-21-Sentiment Analysis.pdf170851960878737112024-02-21T12:46:48.807Z"632d622a1bf1659424e1e9b787cc98af"257992transcripts/event-126/Annual Report 2022/2023 Presentation-CS Medica-2024-02-21.pdf170851960558163212024-02-21T12:46:45.642Z"54ea9e6ccc27c5b37d07b67cc489580a"257178transcripts/event-131/Annual Report presentation and Q&A-Virogates-2024-03-21-Sentiment Analysis.pdf171104690699418112024-03-21T18:48:27.016Z"473eb418c198134e7257a7b977bedb6f"242737transcripts/event-131/Annual Report presentation and Q&A-Virogates-2024-03-21.pdf171104690532065812024-03-21T18:48:25.343Z"4d285fc00593645716b366c6e97a0e1d"242449transcripts/event-132/Q4 and FY2023 presentation and Q&A-Movinn-2024-04-03-Sentiment Analysis.pdf171215776476252912024-04-03T15:22:44.783Z"e8c0efc959f885258c80dc271f0a9f77"263081transcripts/event-132/Q4 and FY2023 presentation and Q&A-Movinn-2024-04-03.pdf171215776261966412024-04-03T15:22:42.645Z"2c917322a6e2422912169fe88745ad4d"262264transcripts/event-133/Q1 2024 Presentation and Q&A-Konsolidator-2024-04-30-Sentiment Analysis.pdf171645652960445912024-05-23T09:28:49.719Z"c968038a66db38671211797a738938f3"238833transcripts/event-133/Q1 2024 Presentation and Q&A-Konsolidator-2024-04-30.pdf171645652696016812024-05-23T09:28:47.075Z"055e793fb53fe339896fc34114aa116a"238360transcripts/event-134/Q2 2024 Presentation and Q&A-Konsolidator-2024-08-22-Sentiment Analysis.pdf172432902270142712024-08-22T12:17:02.728Z"b9fbebb34463168d5c535cc4bc9e2a6e"237989transcripts/event-134/Q2 2024 Presentation and Q&A-Konsolidator-2024-08-22.pdf172432902095402212024-08-22T12:17:00.981Z"792282c1db8a8158686bad0b772ce6b8"237590transcripts/event-135/Q3 2024 Presentation and Q&A-Konsolidator-2024-11-07-Sentiment Analysis.pdf173099285560222012024-11-07T15:20:55.623Z"c9fcfa2c28a050677adaf40ccb71bf43"233295transcripts/event-135/Q3 2024 Presentation and Q&A-Konsolidator-2024-11-07.pdf173099285399697712024-11-07T15:20:54.022Z"9996e9bc1305740ed2dc8a555c9b154f"232954transcripts/event-136/2023 Report presentation and Q&A-RISMA Systems-2024-04-05-Sentiment Analysis.pdf171231757725988512024-04-05T11:46:17.281Z"caf38d4f4056200a1652fd7d6dba3638"237951transcripts/event-136/2023 Report presentation and Q&A-RISMA Systems-2024-04-05.pdf171231757533337612024-04-05T11:46:15.357Z"9f7267d881720350318967c9597248fe"237565transcripts/event-137/2023 Report presentation and Q&A-Wirtek-2024-04-02-Sentiment Analysis.pdf171206947808659012024-04-02T14:51:18.111Z"9e7412a22d67b02427a9e6773db1a8cd"238825transcripts/event-137/2023 Report presentation and Q&A-Wirtek-2024-04-02.pdf171206947610780312024-04-02T14:51:16.135Z"78fd48b273463a687ac7c8bd1327661f"238385transcripts/event-138/Annual Report 2023 presentation and Q&A-MapsPeople-2024-03-21-Sentiment Analysis.pdf171104695690624612024-03-21T18:49:16.928Z"c95b0cbf8e245b24ef2803a38b962369"251681transcripts/event-138/Annual Report 2023 presentation and Q&A-MapsPeople-2024-03-21.pdf171104695483390612024-03-21T18:49:14.857Z"218e4363607f85d0fd57d286dc0578f5"251007transcripts/event-139/Q4 2023 Presentation and Q&A-CS Medica-2024-04-12-Sentiment Analysis.pdf171328060846063812024-04-16T15:16:48.485Z"ed87fec2e6f0b7e12ae07836db870310"237495transcripts/event-139/Q4 2023 Presentation and Q&A-CS Medica-2024-04-12.pdf171328060671787112024-04-16T15:16:46.745Z"42cafd3d8eb40daf874f67c713b1bc94"237199transcripts/event-140/Q1 Investor Update-FOM Technologies-2024-04-10-Sentiment Analysis.pdf171282924195861412024-04-11T09:54:01.980Z"4e9eb46fb1be2d1e927550c217942adc"237705transcripts/event-140/Q1 Investor Update-FOM Technologies-2024-04-10.pdf171282923981924712024-04-11T09:53:59.844Z"4350b854d49aa80872f53a81024ae914"237414transcripts/event-141/Q1 2024 presentation and Q&A-Stenocare-2024-05-02-Sentiment Analysis.pdf171465000491828912024-05-02T11:40:04.993Z"0900dfc0bc09103c0d115c937e101a1c"249464transcripts/event-141/Q1 2024 presentation and Q&A-Stenocare-2024-05-02.pdf171465000182968712024-05-02T11:40:01.905Z"ae26e2efbbcac2c321aa8ce09a1b2812"249122transcripts/event-142/2024 Outlook and Q&A-Pila Pharma-2024-04-22-Sentiment Analysis.pdf171378437168293212024-04-22T11:12:51.755Z"05067ec96ff8864ff90015ae67bdf9f8"231210transcripts/event-142/2024 Outlook and Q&A-Pila Pharma-2024-04-22.pdf171378436940691312024-04-22T11:12:49.492Z"a1caa0c36d2c736c42b9d179730e30b4"231109transcripts/event-143/Q1 2024 Presentation and Q&A-Virogates-2024-05-03-Sentiment Analysis.pdf171473012792511012024-05-03T09:55:27.944Z"a05051aa71cb4577c971daa54cb3cb11"237735transcripts/event-143/Q1 2024 Presentation and Q&A-Virogates-2024-05-03.pdf171473012566327012024-05-03T09:55:25.682Z"64220ac0fc8fa2dfb23cd52057fb7e85"237446transcripts/event-144/Q1 2024 Presentation and Q&A-Solar-2024-05-02-Sentiment Analysis.pdf171472796630247212024-05-03T09:19:26.377Z"eadf23d32e060bffddb22b8abf5972cb"232460transcripts/event-144/Q1 2024 Presentation and Q&A-Solar-2024-05-02.pdf171472796280386212024-05-03T09:19:22.878Z"4f842d1821245e6ca1e6105e63aff278"232194transcripts/event-145/Q1 2024 Presentation and Q&A-MapsPeople-2024-05-23-Sentiment Analysis.pdf171648693768572912024-05-23T17:55:37.702Z"29a8461a72e59894824d16f0ec2418de"245385transcripts/event-145/Q1 2024 Presentation and Q&A-MapsPeople-2024-05-23.pdf171648693596467212024-05-23T17:55:35.985Z"ca3b7c878c8100426e95d94855b7d611"244652transcripts/event-146/Q2 2024 Presentation and Q&A-Scandinavian Medical Solutions-2024-05-21-Sentiment Analysis.pdf171630424489079912024-05-21T15:10:44.959Z"2f23edd3805c9fc8009d01bea6d1b158"238650transcripts/event-146/Q2 2024 Presentation and Q&A-Scandinavian Medical Solutions-2024-05-21.pdf171630424280373312024-05-21T15:10:42.877Z"30565f2daf1a716d37f5b7c7681d3df9"238354transcripts/event-147/Q1 2024 Presentation and Q&A-Risk Intelligence-2024-05-22-Sentiment Analysis.pdf171639335596614412024-05-22T15:55:56.042Z"a6c6e4f4cf262d69d6b5aee33b8a6d8f"229960transcripts/event-147/Q1 2024 Presentation and Q&A-Risk Intelligence-2024-05-22.pdf171639335449526712024-05-22T15:55:54.602Z"63861be993002c6530d9cd145a3ae9a2"229713transcripts/event-148/Q1 2024 Presentation and Q&A-Movinn-2024-05-14-Sentiment Analysis.pdf171569887416685212024-05-14T15:01:14.237Z"c0cda677c565c7d8c757be606e8c5b92"250367transcripts/event-148/Q1 2024 Presentation and Q&A-Movinn-2024-05-14.pdf171569886995054412024-05-14T15:01:10.016Z"7d8372b62959f46ee16c901b6945219e"249764transcripts/event-149/Q3 2023/24 Præsentation og Q&A-FreeTrailer-2024-05-31-Sentiment Analysis.pdf171716239275752712024-05-31T13:33:12.834Z"4ae2fed82d7138402d7d5017734152a7"246846transcripts/event-149/Q3 2023/24 Præsentation og Q&A-FreeTrailer-2024-05-31.pdf171716239070717212024-05-31T13:33:10.826Z"ec39cfd4aed81219277391b6e3b57b7d"246743transcripts/event-151/Q4 2023/24 præsentation og Q&A-Dataproces Group-2024-06-24-Sentiment Analysis.pdf171922292304602712024-06-24T09:55:23.079Z"7e5127c1e1a9426607c8cd23edc40a60"235518transcripts/event-151/Q4 2023/24 præsentation og Q&A-Dataproces Group-2024-06-24.pdf171922292144813412024-06-24T09:55:21.509Z"92ef2c919c1483a91824750621a855ba"235247transcripts/event-152/Investor Update w. New Chairman-Brain+-2024-05-27-Sentiment Analysis.pdf171682674158456912024-05-27T16:19:01.601Z"450e6f5b89034dcef2537202941358f0"252249transcripts/event-152/Investor Update w. New Chairman-Brain+-2024-05-27.pdf171682673942564412024-05-27T16:18:59.444Z"33f872e79583651135589e88f4879d85"251928transcripts/event-153/H1 2023/24 Presentation and Q&A-CS Medica-2024-05-23-Sentiment Analysis.pdf171649045152171312024-05-23T18:54:11.540Z"4f79e5c59945bf2b503741a4c76a7fc4"249091transcripts/event-153/H1 2023/24 Presentation and Q&A-CS Medica-2024-05-23.pdf171649044798876112024-05-23T18:54:08.012Z"b6ce1dbaa69fe9edf7b4f1f0f8d153f1"248607transcripts/event-155/Investor Update & Rights Issue Kick-off-Brain+-2024-06-11-Sentiment Analysis.pdf171818778776668612024-06-12T10:23:07.783Z"81a10fae333c6f750997929f54f152c0"254019transcripts/event-155/Investor Update & Rights Issue Kick-off-Brain+-2024-06-11.pdf171818778500145912024-06-12T10:23:05.019Z"da334cbdc767376da08a4171a2b3074d"253676transcripts/event-156/Investor Presentation-Pharma Equity Group-2024-06-11-Sentiment Analysis.pdf171811931861075812024-06-11T15:21:58.629Z"95045cb592c32b1a2edaa123f811f346"235810transcripts/event-156/Investor Presentation-Pharma Equity Group-2024-06-11.pdf171811931692646212024-06-11T15:21:56.950Z"739be7f388c15cf41c334ed9dcca1b75"235729transcripts/event-157/Investor Presentation-Q-Interline-2024-06-11-Sentiment Analysis.pdf171819561437444612024-06-12T12:33:34.448Z"aa619767d60754164ef67f7f4686d7cb"254306transcripts/event-157/Investor Presentation-Q-Interline-2024-06-11.pdf171819561012014512024-06-12T12:33:30.207Z"baf9ed21ad68058864095ade14da10fe"253920transcripts/event-159/Investor Presentation-Stenocare-2024-06-17-Sentiment Analysis.pdf171863283373004112024-06-17T14:00:33.746Z"a093b5746941efd6808293e382e0db2e"233987transcripts/event-159/Investor Presentation-Stenocare-2024-06-17.pdf171863283221025112024-06-17T14:00:32.243Z"0503bc84f0d9d84583c1510988298c04"233772transcripts/event-161/H1 Presentation and Q&A-Pila Pharma-2024-08-27-Sentiment Analysis.pdf172476532573796412024-08-27T13:28:45.777Z"a72959ed6893659492cb4282daf0aefa"236539transcripts/event-161/H1 Presentation and Q&A-Pila Pharma-2024-08-27.pdf172476532417301712024-08-27T13:28:44.207Z"f6282e8206ef01cd9df1344496351a7b"236252transcripts/event-162/Q2 Presentation and Q&A-Curasight-2024-08-29-Sentiment Analysis.pdf172493253496590312024-08-29T11:55:35.040Z"6dd8000bc74f45599ec5ae8e9da4ec93"242808transcripts/event-162/Q2 Presentation and Q&A-Curasight-2024-08-29.pdf172493253305707712024-08-29T11:55:33.148Z"506e88930a8dbf2cb6b737cbc2a3d512"242624transcripts/event-163/Q1 2024/25 præsentation og Q&A-Dataproces Group-2024-08-30-Sentiment Analysis.pdf172502233262736712024-08-30T12:52:12.648Z"2bf7288eb4bd7b331e7894f4551dfd5e"231359transcripts/event-163/Q1 2024/25 præsentation og Q&A-Dataproces Group-2024-08-30.pdf172502233095906812024-08-30T12:52:11.008Z"26ddc4c37faef118d91648a7ced80072"231088transcripts/event-164/Q2 2024 Presentation and Q&A-Risk Intelligence-2024-08-15-Sentiment Analysis.pdf172379694042786912024-08-16T08:29:00.452Z"95ac3268eba49c634e250cebce4462ef"237358transcripts/event-164/Q2 2024 Presentation and Q&A-Risk Intelligence-2024-08-15.pdf172379693884834512024-08-16T08:28:58.877Z"dd8edbacacb4ce4da6384fd80070a816"237092transcripts/event-165/Q2 2024 Presentation and Q&A-Virogates-2024-08-15-Sentiment Analysis.pdf172379956880423712024-08-16T09:12:48.827Z"e0fdf8936e0ed1bb8b980e57e94c6ebc"240594transcripts/event-165/Q2 2024 Presentation and Q&A-Virogates-2024-08-15.pdf172379956689377812024-08-16T09:12:46.918Z"7bf1c2f99bda4ec3c2d3d6d919f3f2cd"240452transcripts/event-166/Q2 2024 Presentation and Q&A-Solar-2024-08-08-Sentiment Analysis.pdf172734810316235712024-09-26T10:55:03.235Z"f84720f3601df08a1a0b5e43e7150333"245449transcripts/event-166/Q2 2024 Presentation and Q&A-Solar-2024-08-08.pdf172734810036978612024-09-26T10:55:00.470Z"1960f104054b4572784771b9566a7a68"244914transcripts/event-167/Q2 2024 Presentation and Q&A-MapsPeople-2024-08-21-Sentiment Analysis.pdf172425365059935312024-08-21T15:20:50.624Z"85cbdba2d4b78b268f9ff9bbc4213602"247959transcripts/event-167/Q2 2024 Presentation and Q&A-MapsPeople-2024-08-21.pdf172425364880541712024-08-21T15:20:48.832Z"4f776d7065b431f67b06b7b1b6c5447e"247314transcripts/event-169/H1 2024 Presentation and Q&A-RISMA Systems-2024-09-02-Sentiment Analysis.pdf172528549415991112024-09-02T13:58:14.181Z"0a6b4cc1d4690aee3ae05b0305b71160"229524transcripts/event-169/H1 2024 Presentation and Q&A-RISMA Systems-2024-09-02.pdf172528549259010612024-09-02T13:58:12.640Z"067f08c029178440af52ee1e1037facb"229271transcripts/event-170/Q2 2024 Presentation and Q&A-Movinn-2024-09-03-Sentiment Analysis.pdf172537132473891712024-09-03T13:48:44.808Z"51e499b31b8dcf1081b20a94fb7f5c60"253628transcripts/event-170/Q2 2024 Presentation and Q&A-Movinn-2024-09-03.pdf172537132248103312024-09-03T13:48:42.556Z"3833ed858328ea30b056a0812976a66c"253080transcripts/event-171/H1 Presentation & New CCO-Brain+-2024-09-03-Sentiment Analysis.pdf172543142143256712024-09-04T06:30:21.457Z"9c42da1b1010aa5845fdec0c02358492"262467transcripts/event-171/H1 Presentation & New CCO-Brain+-2024-09-03.pdf172543141934668812024-09-04T06:30:19.372Z"3f31694d43a465305f6fdb978d4013c6"261988transcripts/event-172/New branding-, Product Roadmap, Commercial- & TO4 update-Brain+-2024-09-23-Sentiment Analysis.pdf172716464141447112024-09-24T07:57:21.442Z"a6dcb158679b97186aa35ac8edb17717"248105transcripts/event-172/New branding-, Product Roadmap, Commercial- & TO4 update-Brain+-2024-09-23.pdf172716463880020012024-09-24T07:57:18.821Z"8b4759e325130399581b59e77e7a73f3"247771transcripts/event-173/Q4 23/24 Præsentation og Q&A-FreeTrailer-2024-10-22-Sentiment Analysis.pdf172961136379216812024-10-22T15:36:03.814Z"798cf32dac8fb0bba448ba97ab4414aa"245290transcripts/event-173/Q4 23/24 Præsentation og Q&A-FreeTrailer-2024-10-22.pdf172961136080267112024-10-22T15:36:00.828Z"797f5344769341cea497adf0c0f6d3e9"245246transcripts/event-174/Q4 2024 Presentation and Q&A-Konsolidator-2025-02-06-Sentiment Analysis.pdf173885288131850912025-02-06T14:41:21.389Z"ff1488b89d9399630028900a144d5272"235522transcripts/event-174/Q4 2024 Presentation and Q&A-Konsolidator-2025-02-06.pdf173885287868203512025-02-06T14:41:18.757Z"498de9a7c030e74822952fc21d4c137c"235245transcripts/event-175/Q1 Business Update: ARR reporting-Konsolidator-2025-04-24-Sentiment Analysis.pdf174549609882488912025-04-24T12:01:38.849Z"3ee0b23ba947c439af35b587fcd21b24"234011transcripts/event-175/Q1 Business Update: ARR reporting-Konsolidator-2025-04-24.pdf174549609719830812025-04-24T12:01:37.233Z"7df1d20db5cfa4672783f71713f397ce"233645transcripts/event-176/Q2 2025 Presentation and Q&A-Konsolidator-2025-08-21-Sentiment Analysis.pdf175578221969792912025-08-21T13:16:59.721Z"56aaf751283365d14c12a1ef809c4c7b"235920transcripts/event-176/Q2 2025 Presentation and Q&A-Konsolidator-2025-08-21.pdf175578221814635412025-08-21T13:16:58.169Z"dffd6f2c1c8e5ad463a245a4cc42652f"235526transcripts/event-177/Q3 2024 Presentation and Q&A-Wirtek-2024-11-13-Sentiment Analysis.pdf173150924513970412024-11-13T14:47:25.211Z"7b9322f1a611f84fd77370da232ae5d6"228978transcripts/event-177/Q3 2024 Presentation and Q&A-Wirtek-2024-11-13.pdf173150924354417912024-11-13T14:47:23.654Z"a96c8c0f7713f300232042de52d7d50f"228584transcripts/event-178/Investor After-work Q&A-Pila Pharma-2024-10-28-Sentiment Analysis.pdf173013527872713812024-10-28T17:07:58.755Z"af9237989d3d1beb1d5e4916daf5d238"247158transcripts/event-178/Investor After-work Q&A-Pila Pharma-2024-10-28.pdf173013527684066412024-10-28T17:07:56.866Z"d4fe51a691ea7f8315b640acd3ad7c21"246952transcripts/event-180/Q3 2024 Presentation and Q&A-MapsPeople-2024-11-14-Sentiment Analysis.pdf173158268588416312024-11-14T11:11:25.925Z"e833de6794246ab80183595525f6c889"239751transcripts/event-180/Q3 2024 Presentation and Q&A-MapsPeople-2024-11-14.pdf173158268425502312024-11-14T11:11:24.295Z"37be287e1d3cbb508210ba4e3216b9e3"239157transcripts/event-181/Capital Increase: How, Why & Next Step-Pharma Equity Group-2024-10-23-Sentiment Analysis.pdf172968812463957012024-10-23T12:55:24.667Z"86a5292a5f6e15a09b705febd5cae850"228900transcripts/event-181/Capital Increase: How, Why & Next Step-Pharma Equity Group-2024-10-23.pdf172968812293497912024-10-23T12:55:22.975Z"fdabcce27c177b037da47d4e89074380"228727transcripts/event-183/Q3 2024 Presentation and Q&A-Solar-2024-10-31-Sentiment Analysis.pdf173038614172594612024-10-31T14:49:01.751Z"fe8e8423a43e824e383d71c0c3cdcf85"236044transcripts/event-183/Q3 2024 Presentation and Q&A-Solar-2024-10-31.pdf173038614006244512024-10-31T14:49:00.091Z"e29b030fb0d8f8bef0d59157d7f0c8de"235684transcripts/event-184/Q3 2024 Presentation and Q&A-Virogates-2024-11-08-Sentiment Analysis.pdf173107235287004312024-11-08T13:25:52.908Z"aa3403ea09cbbc55184a678899ab3b3e"237447transcripts/event-184/Q3 2024 Presentation and Q&A-Virogates-2024-11-08.pdf173107235127253612024-11-08T13:25:51.295Z"1713f1aacfec0ee6f9102891e7d9f3ce"237222transcripts/event-185/Q3 2024 Presentation and Q&A-Movinn-2024-11-12-Sentiment Analysis.pdf173142027187236012024-11-12T14:04:31.893Z"37dd60834b49d9e58624990cf2c67d54"240683transcripts/event-185/Q3 2024 Presentation and Q&A-Movinn-2024-11-12.pdf173142027010709912024-11-12T14:04:30.130Z"445b8723971e7f86caeced049a7a9a71"240034transcripts/event-186/Q2 2024/25 præsentation og Q&A-Dataproces Group-2024-12-17-Sentiment Analysis.pdf173443925068309012024-12-17T12:40:50.707Z"fd79257c25ebce087dc8fb1fc2313e07"238625transcripts/event-186/Q2 2024/25 præsentation og Q&A-Dataproces Group-2024-12-17.pdf173443924889279312024-12-17T12:40:48.918Z"67e145888ff6d92789c7155954dff11a"238535transcripts/event-187/Q4 2024 Presentation and Q&A-Scandinavian Medical Solutions-2024-11-21-Sentiment Analysis.pdf173220633965036612024-11-21T16:25:39.672Z"3a14bcc1622d11a6ce6c49c4f759f2ef"237411transcripts/event-187/Q4 2024 Presentation and Q&A-Scandinavian Medical Solutions-2024-11-21.pdf173220633816989712024-11-21T16:25:38.203Z"e683de40784a5c5ac113a24663381a25"237081transcripts/event-188/Q3 2024 Presentation and Q&A-Risk Intelligence-2024-11-21-Sentiment Analysis.pdf173220500709768912024-11-21T16:03:27.120Z"9a9328c109c1c1bf767e077e6e4be9a2"230560transcripts/event-188/Q3 2024 Presentation and Q&A-Risk Intelligence-2024-11-21.pdf173220500494817812024-11-21T16:03:24.971Z"e6e6a908eaafae0295def970f148f4cb"230367transcripts/event-190/Q3 2024 Presentation and Q&A-Stenocare-2024-11-29-Sentiment Analysis.pdf173288696074567012024-11-29T13:29:20.785Z"bed5dd40e77ef494365ccc2836ba3e11"235812transcripts/event-190/Q3 2024 Presentation and Q&A-Stenocare-2024-11-29.pdf173288695915502312024-11-29T13:29:19.195Z"964cb9e1fab2a1b3c056b971acdc67de"235510transcripts/event-191/DanBAN 3.0 - orienteringsmøde: DanBAN Networks-DanBAN-2024-12-02-Sentiment Analysis.pdf173316510335781112024-12-02T18:45:03.429Z"44f0654d77da7363ddcd14b570966d70"245615transcripts/event-191/DanBAN 3.0 - orienteringsmøde: DanBAN Networks-DanBAN-2024-12-02.pdf173316510147298112024-12-02T18:45:01.552Z"df617c827f37b883fc38844975bbe163"245528transcripts/event-192/DanBAN 3.0 - orienteringsmøde: DanBAN Lead Angel Korps-DanBAN-2024-12-04-Sentiment Analysis.pdf173333066997391412024-12-04T16:44:30.055Z"c35605643f2cfccee12036eade12398d"237556transcripts/event-192/DanBAN 3.0 - orienteringsmøde: DanBAN Lead Angel Korps-DanBAN-2024-12-04.pdf173333066761827812024-12-04T16:44:27.723Z"abf46b42ac03bb0f6fd9ea54c4564229"237488transcripts/event-193/Brain+ update: Commercial status and new opportunities-Brain+-2024-11-25-Sentiment Analysis.pdf173255012584369112024-11-25T15:55:25.867Z"89c8527589ff57cd0e32cfd1c6ac2cf7"259513transcripts/event-193/Brain+ update: Commercial status and new opportunities-Brain+-2024-11-25.pdf173255012309537112024-11-25T15:55:23.122Z"7f8a82a183d586cf2cac478fb455b8b3"259105transcripts/event-194/UK Commercial Pipeline update-Brain+-2024-12-11-Sentiment Analysis.pdf173394601374499012024-12-11T19:40:13.767Z"022a4f41e79c6d8e705237b9f358bb6f"240346transcripts/event-194/UK Commercial Pipeline update-Brain+-2024-12-11.pdf173394601198861012024-12-11T19:40:12.012Z"3f395b9ea0816faadc44f4e0f81d4ffb"240232transcripts/event-195/Investering i den globale sundhedssektor - udfordringer og muligheder-Global Health Invest-2025-01-07-Sentiment Analysis.pdf173633342546960212025-01-08T10:50:25.499Z"9f3e4a0d6cce90c0510faa4f1e1645bd"252810transcripts/event-195/Investering i den globale sundhedssektor - udfordringer og muligheder-Global Health Invest-2025-01-07.pdf173633342283166212025-01-08T10:50:22.875Z"5da34cb1bcba23e31d1795b1c92411cd"252693transcripts/event-196/Restructuring, Rights Issue, and UK sales outlook-Brain+-2025-02-03-Sentiment Analysis.pdf173859908396519012025-02-03T16:11:23.991Z"4da489c85a1944949fbf26dc417ad792"259569transcripts/event-196/Restructuring, Rights Issue, and UK sales outlook-Brain+-2025-02-03.pdf173859908199653512025-02-03T16:11:22.045Z"a9421c8d0591274526b138dba12caa71"259213transcripts/event-197/Q4 2024 Presentation and Q&A-Solar-2025-02-06-Sentiment Analysis.pdf173904665365077012025-02-08T20:30:53.672Z"5648421b2af821e3db354d68cfadacbb"243769transcripts/event-197/Q4 2024 Presentation and Q&A-Solar-2025-02-06.pdf173904665213571512025-02-08T20:30:52.171Z"3e266345149e7db8452ed54f1c897dfa"243086transcripts/event-199/Q3 2024/25 præsentation og Q&A-Dataproces Group-2025-03-06-Sentiment Analysis.pdf174159985323411712025-03-10T09:44:13.306Z"769bad2ebff8aec5e3092989a409ba2c"250467transcripts/event-199/Q3 2024/25 præsentation og Q&A-Dataproces Group-2025-03-06.pdf174159985096536312025-03-10T09:44:11.040Z"2ae81d0168f7562502509afc16c21187"250346transcripts/event-200/Q4 2024/25 præsentation og Q&A-Dataproces Group-2025-06-20-Sentiment Analysis.pdf175067797843632612025-06-23T11:26:18.510Z"07a096216df08eecaed07513cde3eb3d"248893transcripts/event-200/Q4 2024/25 præsentation og Q&A-Dataproces Group-2025-06-20.pdf175067797685887112025-06-23T11:26:16.934Z"2a4ca5c4c78200208412987ec3f8f23e"248558transcripts/event-201/Q4 2024 Presentation and Q&A-Risk Intelligence-2025-03-03-Sentiment Analysis.pdf174107046065970112025-03-04T06:41:00.685Z"2f357fb72acafff98a9aaac33d4ce2e6"227569transcripts/event-201/Q4 2024 Presentation and Q&A-Risk Intelligence-2025-03-03.pdf174107045921035612025-03-04T06:40:59.238Z"be62e8f7f3b234a6fe816d2833111e6e"227268transcripts/event-202/H2 Presentation and Q&A-Pila Pharma-2025-02-27-Sentiment Analysis.pdf174068565474702112025-02-27T19:47:34.772Z"354351eb54045becc37cf15463287642"243065transcripts/event-202/H2 Presentation and Q&A-Pila Pharma-2025-02-27.pdf174068565308933612025-02-27T19:47:33.115Z"9367deb53c12ccd055728e06510862bb"242719transcripts/event-203/Annual Report 2024 presentation and Q&A-MapsPeople-2025-03-10-Sentiment Analysis.pdf174163546442181512025-03-10T19:37:44.443Z"658b7c885627021ae6c633a75086209c"239878transcripts/event-203/Annual Report 2024 presentation and Q&A-MapsPeople-2025-03-10.pdf174163546270340312025-03-10T19:37:42.727Z"27c916f0c2d24d6c95567fe80a112353"239509transcripts/event-204/Q2 24/25 Præsentation og Q&A-FreeTrailer-2025-02-24-Sentiment Analysis.pdf174040957858675412025-02-24T15:06:18.608Z"892282570e4ed8638f74e4611aa9da6f"253712transcripts/event-204/Q2 24/25 Præsentation og Q&A-FreeTrailer-2025-02-24.pdf174040957582983912025-02-24T15:06:15.871Z"7c6fcb2bcaf856d23f6115df3c785dc2"253396transcripts/event-206/Annual Report Presentation and Q&A-Virogates-2025-03-21-Sentiment Analysis.pdf174256721079510712025-03-21T14:26:50.815Z"a4048c455fda16dffa939eff412ae88b"240799transcripts/event-206/Annual Report Presentation and Q&A-Virogates-2025-03-21.pdf174256720916590912025-03-21T14:26:49.206Z"6e5db088e25902eddc2afa3af17d6457"240555transcripts/event-207/New UK Board Candidate, sales pipeline progress and Unit Rights Issue-Brain+-2025-03-21-Sentiment Analysis.pdf174281628082180312025-03-24T11:38:00.846Z"7ec57a8501f6d0394489163d8b4658c2"251013transcripts/event-207/New UK Board Candidate, sales pipeline progress and Unit Rights Issue-Brain+-2025-03-21.pdf174281627909458812025-03-24T11:37:59.157Z"743f662488979410bb18ef33d17a8826"250792transcripts/event-208/Status på den globale sundhedssektor i en økonomisk og geopolitisk usikker tid-Global Health Invest-2025-04-02-Sentiment Analysis.pdf174375410504130112025-04-04T08:08:25.063Z"d2a4393220e1a3270aed4e772a286e85"261568transcripts/event-208/Status på den globale sundhedssektor i en økonomisk og geopolitisk usikker tid-Global Health Invest-2025-04-02.pdf174375410176167412025-04-04T08:08:21.783Z"747a12f6f5cac8d85ac3c5b68c9f208d"261119transcripts/event-209/Q1 2025 Presentation and Q&A-Risk Intelligence-2025-05-22-Sentiment Analysis.pdf174792213915164712025-05-22T13:55:39.176Z"066e215ca3e8ae961a312815318a389c"230251transcripts/event-209/Q1 2025 Presentation and Q&A-Risk Intelligence-2025-05-22.pdf174792213777543112025-05-22T13:55:37.814Z"5cf456196420b42d31110379989a21a3"230115transcripts/event-210/Q1 Presentation and Q&A-Virogates-2025-05-05-Sentiment Analysis.pdf174651273521740612025-05-06T06:25:35.241Z"57d527e9c54726ca726fd976abbdf31a"233162transcripts/event-210/Q1 Presentation and Q&A-Virogates-2025-05-05.pdf174651273367173312025-05-06T06:25:33.697Z"93fe0b06c0b01845aba732ef73d35e89"233035transcripts/event-211/Q1 2025 Presentation and Q&A-Solar-2025-05-09-Sentiment Analysis.pdf174703196401100912025-05-12T06:39:24.033Z"5c4ec079393b3c8dfcd37ee2c6ccdeb8"238252transcripts/event-211/Q1 2025 Presentation and Q&A-Solar-2025-05-09.pdf174703196256064512025-05-12T06:39:22.584Z"a4fcbb9e7242166dd99716b9df548c53"237804transcripts/event-213/How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla - featuring Antony Hall, new Brain+ advisor-Brain+-2025-06-10-Sentiment Analysis.pdf174964550937209312025-06-11T12:38:29.398Z"3e7f7e8b5a0f758cfb743646b665986b"246985transcripts/event-213/How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla - featuring Antony Hall, new Brain+ advisor-Brain+-2025-06-10.pdf174964550745612512025-06-11T12:38:27.498Z"bee6ba83f873f2966ce3aa68244935e3"246644transcripts/event-215/Q2 2025 Presentation and Q&A-Risk Intelligence-2025-08-21-Sentiment Analysis.pdf175580451624897912025-08-21T19:28:36.277Z"cf19bea62916d39b0d88296f7ce8ba6b"223193transcripts/event-215/Q2 2025 Presentation and Q&A-Risk Intelligence-2025-08-21.pdf175580451479839012025-08-21T19:28:34.825Z"5192d2b1c485d7988cd30d1cb983da36"223076transcripts/event-219/Presentation of Half Year 2025 report with focus on business update and outlook-Brain+-2025-09-04-Sentiment Analysis.pdf175705511620745712025-09-05T06:51:56.231Z"e5c3f30e052ca2250026889210fb90db"261854transcripts/event-219/Presentation of Half Year 2025 report with focus on business update and outlook-Brain+-2025-09-04.pdf175705511421485912025-09-05T06:51:54.238Z"27d34769dac61727e56fb3ae03b1108f"261216transcripts/event-224/Q3 2025 Presentation and Q&A-Risk Intelligence-2025-11-20-Sentiment Analysis.pdf176366549786064712025-11-20T19:04:57.885Z"3a18971053fc9fe27ca1b24a213835fb"229629transcripts/event-224/Q3 2025 Presentation and Q&A-Risk Intelligence-2025-11-20.pdf176366549659730412025-11-20T19:04:56.638Z"f87cc3aa45ede5769f015bde0bd11af2"229430transcripts/event-227/Annual Report Presentation and Q&A-Virogates-2026-03-27-Sentiment Analysis.pdf177485956734844412026-03-30T08:32:47.388Z"59a2652ed55f7c89099766ed931c9951"237006transcripts/event-227/Annual Report Presentation and Q&A-Virogates-2026-03-27.pdf177485956567236412026-03-30T08:32:45.734Z"82fc20ab06c551369a07f358b8a8f304"236822transcripts/event-71/2023-02-28T09:00:00+00:00/Penneo%20Q4%202022%20pr%C3%A6sentation.pdf169333067494356312023-08-29T17:37:54.963Z"61f69e88a910a7df6d2d585aa4ba32f0"23430transcripts/event-73/Movinn Q4 2022 præsentation-Movinn-2023-03-30-Sentiment Analysis.pdf169502588201188412023-09-18T08:31:22.075Z"9449de6d23fb09c05297b253223ce2a1"259188transcripts/event-73/Movinn Q4 2022 præsentation-Movinn-2023-03-30.pdf169502587790224812023-09-18T08:31:18.067Z"261bff89e0d2b60942b0dc927487144f"258193transcripts/event-78/Q1 2023 presentation - 2cureX - 2023-04-12 - Sentiment Analysis.pdf169391945259860012023-09-05T13:10:52.666Z"f394889e9328cc4372deb4b753ba8268"241223transcripts/event-78/Q1 2023 presentation - 2cureX - 2023-04-12.pdf169391945096197912023-09-05T13:10:51.079Z"08a53209944883829c11afa542396797"241197transcripts/event-81/Investor Update - Brain+ - 2023-05-15 - Sentiment Analysis.pdf169390512364271912023-09-05T09:12:03.706Z"473a2462292d32e03de2db59427cd740"251219transcripts/event-81/Investor Update - Brain+ - 2023-05-15.pdf169390452437322912023-09-05T09:02:04.391Z"017b0b65105c6de228b9ab0a62674fe2"250719transcripts/event-83/Presentation of Q1 2023-Curasight-2023-05-31-Sentiment Analysis.pdf169685675420708212023-10-09T13:05:54.270Z"26bb1736d21b4eaeeedba785de17a86a"240469transcripts/event-83/Presentation of Q1 2023-Curasight-2023-05-31.pdf169685675196088712023-10-09T13:05:52.031Z"c3b85c8ef27563f6a014655379fc7054"239446transcripts/event-88/Q2 2023 Presentation-Konsolidator-2023-08-11-Sentiment Analysis.pdf169450026885538712023-09-12T06:31:08.873Z"afe915415255a93e4cd965f6a80993dc"242214transcripts/event-88/Q2 2023 Presentation-Konsolidator-2023-08-11.pdf169450026714434412023-09-12T06:31:07.166Z"09aa2116f24c3bd08f94cac0b8da4e01"241554transcripts/event-89/Q3 2023 Presentation-Konsolidator-2023-11-02-Sentiment Analysis.pdf169893732136970212023-11-02T15:02:01.387Z"18aa331bc4f17fae1c3d038a54c14d12"230698transcripts/event-89/Q3 2023 Presentation-Konsolidator-2023-11-02.pdf169893731957221212023-11-02T15:01:59.591Z"844d41f381cc66e4a69f16b9350b795b"230394transcripts/event-90/Q2 Investor update - 2cureX - 2023-07-12 - Sentiment Analysis.pdf169383848923553812023-09-04T14:41:29.258Z"eb56fd14d2023ec69a28fcc24646c1bd"248145transcripts/event-90/Q2 Investor update - 2cureX - 2023-07-12.pdf169383848753712412023-09-04T14:41:27.556Z"db520bc169e2fa5a0b29b2b656a914b0"247851transcripts/event-90/Q2 Investor update-2cureX-2023-07-12-Sentiment Analysis.pdf169489660877369212023-09-16T20:36:48.837Z"bf3201637e5f67c3fa2ef013b9b16d1c"248150transcripts/event-90/Q2 Investor update-2cureX-2023-07-12.pdf169489660641817712023-09-16T20:36:46.535Z"aa0f1f34ead74b4e781456bb483969ec"249636transcripts/event-91/Q3 2023 presentation-CS Medica-2023-08-08-Sentiment Analysis.pdf170081860366115012023-11-24T09:36:43.730Z"21dbf311ae4478ec03897c5d1c3e72e2"245900transcripts/event-91/Q3 2023 presentation-CS Medica-2023-08-08.pdf170081860141719412023-11-24T09:36:41.494Z"6c8d198803d691a549cf2488e9f829f0"245524transcripts/event-92/H1 2023 presentation-Penneo-2023-08-17-Sentiment Analysis.pdf169717489430230912023-10-13T05:28:14.371Z"099f8a167bd9592290ab400080697a1c"258031transcripts/event-92/H1 2023 presentation-Penneo-2023-08-17.pdf169717489205580812023-10-13T05:28:12.118Z"4e12646bb698b3b1d1e83351f0f59b00"257236transcripts/event-93/Q2 2023 presentation-Shape Robotics-2023-08-29-Sentiment Analysis.pdf169537676087832612023-09-22T09:59:20.942Z"c42aed50be18c967daeabb3af491bb30"261740transcripts/event-93/Q2 2023 presentation-Shape Robotics-2023-08-29.pdf169537675851925212023-09-22T09:59:18.618Z"e9e0d17aa76870e7b7735b686a4fa548"260490transcripts/event-94/H1 2023 presentation-Brain+-2023-09-01-Sentiment Analysis.pdf172717012341115812024-09-24T09:28:43.482Z"ef33c0b6cdc239f7a97ba1ae2a94f6d2"259331transcripts/event-94/H1 2023 presentation-Brain+-2023-09-01.pdf172717012125589612024-09-24T09:28:41.342Z"1a71a398efd9363a349128005ed837e7"258757transcripts/event-95/Q2 2023 presentation-Movinn-2023-08-30-Sentiment Analysis.pdf169490231417503212023-09-16T22:11:54.246Z"69c1e5b95e224af424cd5fa203601f85"260221transcripts/event-95/Q2 2023 presentation-Movinn-2023-08-30.pdf169490231183420412023-09-16T22:11:51.899Z"b977a7b11dee4b35cb084a4fdf25fa32"259442transcripts/event-96/Q2 2023 presentation-Risk Intelligence-2023-08-22-Sentiment Analysis.pdf169450321387167612023-09-12T07:20:13.889Z"dd71d5392e4bf7ae4dd50de7a4589ba0"228680transcripts/event-96/Q2 2023 presentation-Risk Intelligence-2023-08-22.pdf169450320837451512023-09-12T07:20:08.397Z"2e59310a65f151fcbcbfe87d81693541"228450transcripts/event-98/Investor Presentation-DecideAct-2023-08-30-Sentiment Analysis.pdf169545538939517312023-09-23T07:49:49.413Z"25d365d56201c9fb4d16cba8e3b8bf1b"232030transcripts/event-98/Investor Presentation-DecideAct-2023-08-30.pdf169545538754227512023-09-23T07:49:47.560Z"f882090ce3d0c6f81654af91dfc982cc"231707transcripts/event-99/Life Science seminar-Curasight-2023-08-31-Sentiment Analysis.pdf169444863881934612023-09-11T16:10:38.881Z"d743d5c00777045091a85ab3fe90c37d"231378transcripts/event-99/Life Science seminar-Curasight-2023-08-31.pdf169444863690467212023-09-11T16:10:36.966Z"450898ef9be4d8eed14d2f896d8e4616"231124